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BILATERAL BREAST CARCINOMA IN VISCERAL CRISIS
CARCINOMA BILATERAL DE MAMA EN CRISIS VISCERAL
José M. Vela- Ruiz1,2,a, Diana I.Ferrer-Ponce2,b, Miguel J. Sotelo2,c,
Reina Bustamante-Coronado3,d, Nury León-Nué4,e

CLINICAL CASE

ABSTRACT
Bilateral breast carcinoma is rare and infrequent , it is good to define if it occurs synchronously or
metachronously, to define if the lesion in the second breast is metastasis or a primary tumor using
pathological criteria, the state and clinical condition . For the prognosis and specialized treatment to
follow. We present the case of a patient with ECIV breast cancer due to contralateral breast metastasis in
a state of visceral crisis at debut, with pathological anatomy of grade 2 infiltrating ductal carcinoma of
the breast, absent in situ component in both breast , RE (70%) , RP (80%), Cerb2 negative, Ki67 30% in the
right breast and RE (100%) RP (80%) Cerb2-Ki67 20% left breast. A chest-abdomen-pelvis tomography
was performed, showing pleural effusion. bilateral and large volume ascites. It was decided to start
treatment with systemic chemotherapy, reaching a complete radiological and clinical response. After
achieving good control of the disease, the first hormonal line will be sought.
Key words: Infiltrating ductal breast carcinoma; Contralateral metastasis; Visceral crisis (source: MeSH
NLM).

RESUMEN
El carcinoma bilateral de mama es poco frecuente y raro, es bueno definir si ocurre de forma sincrónica
o de forma metacrónica, definir si la lesión en la segunda mama es metástasis o un tumor primario
usando criterios patológicos, el estadío y condición clínica. Ya que orienta en el pronóstico y tratamiento
especializado a seguir. Presentamos el caso de una paciente con cáncer de mama ECIV por metástasis de
mama contralateral en estado de crisis visceral al debut, con anatomía patológica de carcinoma ductal
infiltrante de mama, grado 2, componente in situ ausente en ambas mamas, RE (70%) RP (80%) Cerb2-, Ki67
30% en mama derecha y RE (100%) RP (80%) Cerb2-Ki67 20% en mama izquierda. Se realizó tomografía
de tórax-abdomen-pelvis, evidenciándose derrame pleural bilateral y ascitis en gran volumen. Se decide
iniciar tratamiento con quimioterapia sistémica alcanzándose respuesta completa radiológica y clínica.
Tras conseguir buen control de la enfermedad se decidió iniciar primera línea hormonal.
Palabras clave: Carcinoma ductal infiltrante de mama; Metástasis contralateral; Crisis visceral (fuente:
DeCS BIREME).
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INTRODUCTION
Breast cancer is the most common neoplasm in
women and the 5th leading cause of death around
the world(1).
Bilateral breast cancer (BCC) has an incidence of
approximately 0.7 to 1.8%(2,3) and even in other
literature it is mentioned that there is a risk of
presenting BCC of approximately 0.5% to 0.75%(4,5).

CLINICAL CASE

It is good to define if it occurs synchronously <1 year
according to Heron, or metachronously> 1 year, to
define if the lesion in the 2nd breast is a metastasis
or another primary cancer using the Chaudary
pathological criteria(6,7).
We know that having a BCC have worse prognosis
than unilateral breast cancer(8,9). All this is important
both in the prognosis and specialized treatment(9,10).

CASE REPORT
We present the case of a 48-year-old patient with
no significant family oncological history, no relevant
pathological history, with a 2-year illness time
characterized by asthenia and abdominal pain, who
was admitted by emergency due to exacerbated
dyspnea, marked abdominal distention, whose
preferential physical examination revealed tumors in
both breasts, both on the right side of approximately
5 x 5 cm with an axillary ganglion more or less 2x2 cm
with little hard motility, and a tumor in the left breast
measuring 5 x 5 cm without palpable ganglion.
On examination of the chest and lung: decreased
vesicular murmur at the base with increased vocal
vibrations, at the abdominal level a wave sign +,
displaceable dullness, in lower limbs edemas marked
with fovea ++ / +++ was evidenced.
A biopsy of both breast lesions was performed,
the result being in the right breast was infiltrating
ductal carcinoma of the breast, grade 2, component
in situ absent with immunohistochemistry in which
the estrogen receptor (ER) + 70%, progesterone
receptor (PR) + 80%, Cerb2 negative, Ki67 30%; and
in the left breast, infiltrating ductal carcinoma of
the breast, grade 2, absent in situ component with
immunohistochemistry RE (100%) RP (80%) Cerb2Ki67: 20% (Figure 2 and 3).
The emergency analysis showed hypoxemia due
to AGA: pO2 55 mmHg, gauze ascites fluid study
(blood albumin / ascites gradient (GASA)) <1.1,
negative ascites fluid PAP, leukocyte hemogram
5300 / mm3 (neutrophils 43.2%) with rest of the
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hemogram, coagulation profile and biochemistry
in normal values, for this reason it was decided
to perform a chest-abdomen-pelvis tomography,
showing large volume ascites and bilateral pleural
effusion. (Figure 1)
Considering that the patient was found in visceral
crisis at that time: respiratory failure, ascites and
massive pleural effusion and considering it a case of
clinical stage IV infiltrating lobular breast cancer due
to contralateral breast metastasis according to the
criteria of Chaudary et al., In crisis state visceral, for
which it is decided to start systemic chemotherapy
of the 1st line Adriamycin - Cyclophosphamide
(Cyclophosphamide 600 mg / m2 and doxorubicin
60 mg / m2) 4 courses + 12 courses Paclitaxel (80mg /
m2) weekly with contrast tomographic control chest,
abdomen and pelvis (09-01-18): showing complete
remission of ascites, pleural effusion. (Figure 4).
Bone scan (GGO) 10/17/18: no evidence of metastatic
disease. Clinically, there is a reduction in tumor size
in both breasts, remission of respiratory failure,
and ascites. Being a luminal B patient: she began
treatment with tamoxifen on a palliative basis with
stable disease at the time.

DISCUSION
48-year-old female patient, native and from Lima,
with an illness time of approximately 2 years
characterized by asthenia and abdominal pain.
Whoever is admitted as an emergency due to
exacerbated dyspnea, marked abdominal distention.
On examination of the chest and lung: decreased
vesicular murmur at the base with increased
vocal vibrations compatible with pleural effusion
clinically, at the abdominal level a wave + sign was
evidenced, displaceable dullness compatible with
ascites clinically, in the emergency laboratory tests
hypoxemia due to AGA and related to the respiratory
condition already described. Ascites fluid study
(GASA) <1.1, negative ascitic fluid PAP, with this it
should be remembered that the serum albumin
gradient - ascites: GASA, allows us to identify if the
ascites is due to portal hypertension or other causes.
It is obtained by subtracting the value of serum
albumin minus the albumin of the ascites fluid from
samples obtained on the same day. If it is higher than
1.1g / dl it may be due to cirrhosis, cardiac ascites,
Budd-Chiari syndrome or liver metastasis; if it is <1.1
g / dl, it may be due to peritoneal carcinomatosis,
peritoneal tuberculosis, nephrotic syndrome or
pancreatic ascites.
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For all these reasons, it was decided to perform
a chest, abdomen and pelvic tomography with
contrast, showing bilateral pleural effusion and
marked ascites compatible with the aforementioned
symptoms. (Figure 1)
Preferential physical examination revealed tumors
in both breasts both on the right side with axillary
ganglion present with little hard motility, and a
tumor in the left breast without palpable ganglion,
which suggests that the suggestive symptoms could
be due to a neoplastic process.

In bilateral breast cancer there is an incidence of
approximately 0.7 to 1.8%(2,4,5). It is good to define if
it occurs synchronously <1 year according to Herón,
or metachronously> 1 year, to define if the lesion in
the 2nd breast is a metastasis or 2nd primary cancer
using the Chaudary pathological criteria(6,7). We
know that having a BCC is a worse prognosis than
unilateral breast cancer(8,9). All of this is important
both in the prognosis and specialized treatment(9,10).
We define whether it is really a metastasis or a second
primary tumor using the Chaudary criteria (7), which
are summarized in 4 items:
1. Which describes whether the lesion in the 2nd
breast has an in situ component, makes us suspect
a second primary cancer.
2. If we have a higher degree of differentiation, it is
suggestive of a second primary cancer.
3. If we have a different histology, let's think about a
second primary cancer.
4. Last but not least: if we have similar histologies in
both breasts and with the absence of locoregional
or distant metastasis, it could indicate a second
primary cancer.
Let's report what we have in our patient:
1. In both breasts component in situ absent.
2. Similar degree of differentiation in both tumors
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3. Histology in both breasts as evidenced by
a negative single row and cadherin pattern
indicating invasive lobular carcinoma.
4. Faced with the fourth criterion, our patient
presented a hard, non-mobile axillary adenopathy
that inferred a probability of locoregional
metastasis without even taking into account
ascites and pleural effusion, which could be
considered as distant metastasis.
For all the above, we classify it as a clinical stage IV
breast cancer due to the contralateral breast
We show marked intensity estrogen receptors as
evidenced in right breast (RB), left breast (LB), as well
as similar progesterone + receptors in both breasts,
negative cerb-b2 in RB and LB, ki67 30% in RB and
20% LB : cataloging Luminal B breast cancer.
Our patient is in visceral crisis state because she
presents an organ dysfunction characterized by signs,
symptoms and laboratory tests (dyspnea, ascites,
surge sign +, respiratory failure and hypoxemia
demonstrated by AGA) that show marked clinical
deterioration plus a visceral commitment, which
forces us to act quickly and effectively(11).

CLINICAL CASE

Therefore, it was decided to perform core biopsy
in both breasts with the following histology:
infiltrating carcinoma, intermediate histological
grade, infiltrating lobular carcinoma, ER +. RP +, Cerb
b2 -, Ki 67 left breast: 20%, Ki 67 right breast: 30%
both absence of in situ component, and negative
cadherin, for which we are facing a case of: clinical
stage infiltrating lobular breast cancer stage IV
due to metastases of the contralateral breast. We
consider CS IV based on the pathological criteria of
Chaudary et al.

according to pathology.

Treatment depends on the clinical stage at the
time of diagnosis. Considering a metastatic CS IV , it
should be mentioned that in patients with hormone
receptor (HR) positive metastatic breast cancer,
starting chemotherapy before hormone therapy has
not been shown to increase survival as evidenced
in the Cochrane meta-analysis with studies by
Dixon, Tashiro and Taylor in their respective
investigations(12,13).
We have to take in consideration that currently in
RH positive metastatic breast cancer the standard
first-line treatment is hormone therapy + cyclin CDK
4-6 inhibitors, which has been shown to significantly
prolong progression-free survival in this scenario.
With great examples such as the clinical benefit of
palbociclib as initial therapy for postmenopausal
women with estrogen receptor positive, epidermal
growth factor 2 negative (ER +, HER2-) metastatic
breast cancer, the phase 3 PALOMA-2 study
demonstrated that the combination of palbociclib +
letrozole vs letrozole improved disease-free survival
of 24.8 months vs 14.5 months, showing a net benefit
of 10 months HR 0.58 CI (0.46-0.72), it should also
be noted that the combination of palbociclib and
letrozole exceeded two years of PFS (progression-
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free survival), making it the best first line in this
population of women. Benefit was also mentioned
in the MONALEESA-7 study with hormone therapy
+ ribociclib with 23.8% vs 13.0% PFS HR 0.55 (0.440.69)(14, 15).
However, there is a scenario in which the probability
of starting chemotherapy is indicated: only in the
visceral crisis state according to the NCCN 2020
guidelines(12).

of ascites and pleural effusion Figure 4 GGO, no
metastasis was evident.
In September 2018 we started with tamoxifen until
now with good disease control.
There is little evidence and reported cases of
contralateral metastatic breast cancer at the time of
diagnosis as debut, using the criteria of Chaudary et
al., and that they have responded to chemotherapy
as first line in a state of visceral crisis, prolonging their
disease-free survival, which our work contributes to
the scientific and academic literature.

CLINICAL CASE

In our patient we started with 4 AC cycles and 12
weekly Paclitaxel cycles, showing disappearance

Vela J et al

Figure 1. Contrast chest, abdomen and pelvis tomographic study 07-11-17 showing bilateral pleural
effusion, no pulmonary nodular lesions, free fluid in extensive degree in the intraperitoneal cavity, liver
without solid or cystic focal nodular lesions, retroperitoneum does not show adenopathy no lumps.
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Mama derecha 40 x

Mama izquierda 40 x

Figure 2A. Cellular microscopy of the breast tissue is observed: cell populations in a single-row pattern in
both right and left breast corresponding to invasive lobular carcinoma (H-E staining, 40 X).

Figure 2B. Negative E-cadherin is observed in both breasts, a calcium-mediated glycoprotein related to
epithelial cell adhesion, the absence of which is compatible with lobular carcinoma.
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Immunohistochemistry

Right breast

Left breast

RE(70%) intensity +++

RE(100%) intensity +++

RP (80%) intensity+++

RP(80%) intensity+++

Negative Cerb2

Cerb2-

Ki67 30%

Ki67:20
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Estrogen receptor

Progesterone receptor

C-ERB2

Ki67

Figure 3. Immunohistochemical test for breast cancer, divided into the following categories: estrogen
receptor (ER) / progesterone receptor (PR) positive as luminal A, ER / RP / Her-2 positive as luminal B, Her-2
positive (Her-2 array) and triple negative (basal-like). It is also considered that those tumors that only express
hormone receptors, but the expression of the cell proliferation marker or Ki-67 is greater than 14%, are
classified as luminal B. All this is important for both the prognosis and the respective treatment.
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Figure 4. Tomographic study of the thorax, abdomen and pelvis, 01-09-18, where pulmonary fields with
density and preserved configuration are evidenced, not showing interstitial thickening, consolidation process,
or pulmonary nodules and without evidence of pleural effusion, no fluid is observed in the peritoneal cavity,
remnants of organs and pelvis within normal limits.

CONCLUSION
It is important to differentiate between a second
primary vs metastatic breast cancer due to the
respective prognostic and therapeutic implications.

4/6 inhibitors according to the bibliography and
guidelines.
Patients with visceral crisis are candidates for firstline treatment with CT.

In patients with metastatic RH + breast cancer, the
standard treatment is hormone therapy + CDK

There are few reported cases, it is necessary to
deepen in more studies in breast cancer with
contralateral metastases.
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